45
Participants
Start Date
September 23, 2016
Primary Completion Date
July 31, 2019
Study Completion Date
July 31, 2019
Atezolizumab
Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
Radium-223 Dichloride
Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
Memorial Sloan-Kettering Cancer Center, Commack
Thomas Jefferson University Hospital, Philadelphia
Georgetown University Medical Center, Washington D.C.
Duke University Hospital, Durham
Mayo Clinic Hospital - Florida, Jacksonville
Vanderbilt University Medical Center, Nashville
Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis
University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit
Mayo Clinic - Minnesota, Rochester
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas
City of Hope, Duarte
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
University of Washington, Seattle
Yale School of Medicine, New Haven
Tulane University School of Medicine, New Orleans
University of Pittsburgh - Hillman Cancer Center, Pittsburgh
Hoffmann-La Roche
INDUSTRY